Hepatitis B vaccine birth dose down 2% in children under 2 years old, CDC immunization report finds

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.

March 25, 2026

Cancer Policy

The reconstitution of ACIP and changes to CDC’s childhood vaccine schedule were likely illegal, judge rules

Judge Brian E. Murphy, of the U.S. District Court for the District of Massachusetts, temporarily blocked a series of recent changes to the CDC vaccine schedule.

HPV cancer vaccine slows tumor growth, extends survival in animal models

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

February 13, 2026

Vol.52 No.06

Cancer Policy

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

Pressed by Sen. Bernie Sanders (I-VT), NIH Director Jay Bhattacharya acknowledged that he is not aware of any study pointing to a causal link between vaccines and autism.

Could mRNA vaccines hold the key to building an affordable universal cancer vaccine?

“I believe in the concept of a universal cancer vaccine,” said Elias Sayour, a pediatric oncologist at the University of Florida. “I think if this fails in a prospective phase III trial, I still believe we can engineer a vaccine that works prospectively.”

January 14, 2026

Vol.52 No.1

Clinical

A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

A phase III clinical trial will soon begin testing the evidence collected thus far that points to a stunning prospect: the COVID-19 vaccine—a widely accessible mRNA vaccine already on the market—could make checkpoint inhibitors work better for lung cancer and melanoma patients.

January 09, 2026

Vol.52 No.1

By Sara Willa Ernst and Jacquelyn Cobb

Hepatitis B vaccine birth dose down 2% in children under 2 years old, CDC immunization report finds

YOU MAY BE INTERESTED IN

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

The reconstitution of ACIP and changes to CDC’s childhood vaccine schedule were likely illegal, judge rules

HPV cancer vaccine slows tumor growth, extends survival in animal models

NIH’s Bhattacharya acknowledges absence of causal link between vaccines and autism

Could mRNA vaccines hold the key to building an affordable universal cancer vaccine?

A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?

Renew today!

Subscriber content

Never miss an issue!

Login